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Summary We evaluated asthma control and medication use 5 years after
introduction of an inhaled corticosteroid (budesonide via Turbuhalers) in 462
patients with persistent asthma and symptoms of different duration. An early
treatment group with symptoms for o2 years (group A) was compared with a
delayed treatment group (group B) (median duration 5 years and 3 months). Most
patients received budesonide 400 mg twice daily as initial dose. We report 5-year
follow-up data on 404 patients (group A n ¼ 253; group B n ¼ 151) and on a few more
patients after treatment for 6 months, 1 year and 3 years. At 5 years the mean
maintenance doses of budesonide were 412 mg (A) and 825 mg (B), respectively
(Po0:001). Nevertheless, treatment goals (normal lung function, normal exercise
tolerance, minimal use of reliever medication, no asthma exacerbations) were all
statistically significantly more frequently achieved in group A. At 5 years group B
patients also used significantly more additional asthma medications, e.g. inhaled
long-acting b2-agonists by 64% compared with 6% in group A. In group A 43 patients
(17%) had been able to stop budesonide treatment compared to five patients (3%) in
group B. A subgroup of group B patients with higher mean baseline FEV1 values than
group A showed nevertheless significantly poorer response. No treatment-related
serious adverse events were reported. Budesonide was well tolerated in both groups.
Conclusion: Duration of asthma symptoms when starting treatment with an
inhaled corticosteroid is an important determinant for the response. Early treatment
gives significantly better airway function and asthma control than delayed treatment
and at lower maintenance doses.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Asthma management and treatment guidelines
recommend inhaled corticosteroids as first-line
treatment for patients with mild, moderate or
severe persistent asthma.1,2 For a long time we
have been interested in early use of inhaled
corticosteroids. The first 2-year, double-blind,
parallel-group study in Finland showed that the
inhaled corticosteroid, budesonide, was more
effective than the inhaled b2-agonist, terbutaline,
when given regularly as first-line treatment to
patients with newly detected asthma.3 The follow-
up study, when terbutaline-treated patients re-
ceived budesonide during a third treatment year,
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showed improvements in lung function and reduc-
tions in bronchial hyperresponsiveness (BHR), use
of reliever medication and asthma symptoms, but
the patients did not reach the same level of asthma
control as those patients treated with budesonide
from the beginning.4 Our retrospective analysis
evaluating the relationship between duration of
asthma symptoms and response to treatment with
budesonide supported these results.5 A statistically
significant negative correlation was found between
duration of asthma symptoms and improvements in
lung function (forced expiratory volume in 1 s,
FEV1; peak expiratory flow, PEF). Patients with
symptoms for more than 2 years responded less
well than patients with a shorter duration of
symptoms. The best improvements in lung function
were seen in patients who had had asthma
symptoms for less than 6 months when starting
treatment with budesonide.5 Similar observations
have been reported in children with asthma.6
In the present observational study we started
treatment with budesonide (Pulmicorts Turbuha-
lers, Astra Pharmaceuticals, Sdertlje, Sweden) in a
large series of patients not previously treated with
inhaled corticosteroids. Some 312-year results have
previously been briefly reported.7 The aim of this
paper is to report 6-month, 1-, 3-, and 5-year
follow-up data in patients with asthma starting
treatment with budesonide early, when they had
had asthma symptoms for less than 2 years,
compared to patients who had had symptoms for
a longer period of time.
Material and methods
Study design
Asthma patients seen at the Mjlbolsta hospital in
Finland and not previously treated with an inhaled
corticosteroid were prescribed budesonide as reg-
ular maintenance treatment. They were then
followed at regular intervals, approximately 3, 6
or 12 months apart, when lung function was
measured (FEV1; forced vital capacity, FVC; FEV1%
predicted normal), symptoms, use of reliever
medication and adverse effects recorded, and the
dose of budesonide adjusted up or down depending
on the clinical situation. Before a clinic visit
patients were asked to record morning and evening
PEF for 1–2 weeks. Patients did not themselves
change prescribed doses between visits, but were
allowed to contact the hospital at any time, if
necessary, and then the dose could be adjusted.
Additional asthma medication could be added or
changed as required.
Based on our earlier experiences4,5 we divided
the clinical series into patients with early asthma,
i.e., with asthma symptoms for less than 2 years
when starting treatment with budesonide, and the
rest, i.e., those with delayed treatment with
symptoms for more than 2 years when starting
treatment with budesonide.
The aim was to investigate to what degree the
goals given in asthma treatment guidelines could be
achieved with early vs. delayed treatment with an
inhaled corticosteroid, and how much additional
medication was required, if necessary, to achieve
the best possible result. We also wanted to
investigate to what extent there would be a
difference in response to treatment in terms of
improved airway function between patients with a
short and a long duration of symptoms when
starting treatment with budesonide.
Study population
A total of 462 patients with persistent asthma
started treatment with budesonide Turbuhaler. The
series consists of consecutive patients visiting the
hospital for the first time between 1988 and 1995
and not previously treated with inhaled corticos-
teroids. However, based on hospital statistics we
estimate that approximately 17% of all patients
with persistent asthma and not previously treated
with inhaled corticosteroids did not start or accept
treatment with budesonide at the time of the
study. In patients starting treatment the duration
of asthma symptoms was less than 2 years in 301
(group A; median duration of symptoms 13 months)
and longer in 161 patients (group B; median
duration of symptoms 5 years and 3 months).
Demography and baseline lung function data are
shown in Table 1. The differences between groups A
and B in FEV1 per cent predicted and baseline
reversibility were statistically significant, Po0:01
and Po0:001; respectively. The difference in PD20
histamine mean values was not statistically sig-
nificant.
We have been able to follow 455 patients for 6
months, 433 for 1 year, 418 for 3 years and 404
(87%) patients for 5 years. Five-year data could be
obtained in 253 group A (84%) and 151 group B
patients (94%). The proportion of patients with mild
persistent asthma (FEV1X80% predicted normal)
and moderate-to-severe persistent asthma
(FEV1o80% predicted normal) did not differ
statistically significantly between groups A and B,
indicating that as groups they were similar in terms
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of asthma severity, and thus only differed in terms
of duration of disease. In group A 42% of the
patients had mild persistent asthma (FEV1480%
predicted normal) and in group B 39%. As, however,
the mean level of FEV1 differed statistically
significantly between groups A and B we further
analysed a subgroup of group B patients with
individual FEV1 values X80% predicted normal.
Thus, this subgroup of patients (n ¼ 63) with a
median duration of symptoms of 6 years and 7
months did not have a more severe disease than
group A, but only a longer duration of asthma
symptoms.
Treatment
When inhaled corticosteroid treatment was in-
itiated the starting dose of budesonide was mostly
400 mg twice daily, but varied from 100 to 800 mg
twice daily. The initial dose was maintained until a
normal airway function (or best possible) and good
exercise tolerance had been achieved, the night-
time sleep was undisturbed and the need of
reliever medication (rapid-acting inhaled b2-ago-
nists) reduced to 2–3 doses per week indicating
infrequent symptoms. The daily dose was then
reduced by 200–400 mg per day, which could be
given once daily. When a daily dose of 100–200 mg
had been achieved treatment could be
discontinued and the patient followed in the same
way as before. If necessary, treatment with
budesonide was re-instituted. The degree of BHR
(histamine challenge test) was not used on a
routine basis for adjustment of budesonide
doses. If an acceptable response was not seen the
dose was increased step-wise to a maximum of
2400 mg per day and then adjusted downward, if
possible, as earlier described. Additional asthma
medications could be prescribed as considered
necessary.
During the later part of the study period doses
above 1200 mg per day of budesonide were rarely
used. Instead combination treatment, especially
with long-acting inhaled b2-agonists, was the
preferred treatment.8,9
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Table 1 Demographic data when starting treatment with inhaled budesonide.
Early treatment
(Group A)
Delayed treatment
(Group B)
Total series of patients
Number of patients (%) 301 (65) 161 (35) 462 (100)
Female/Male (%) 172/129 (57/43) 74/87 (46/54) 246/216 (53/47)
Mean age (range),years 34 (16–69) 39 (18–78) 37 (16–78)
Median duration (range)
of asthma symptoms
13 months (3–23 months) 5 years 3 months (2.5–18
years)
FEV1, L (mean7 SD) 3:0670:98 2:4170:81 2:8570:92
FEV1, % pred norm,
mean7 SD
78:6718:1 74:3720:5 77:2718:6
Percentage of patients
with FEV1X 80% pred
normal
42 39 41
Reversibility %, mean7 SD 18:474:3 15:975:8 17:875:6
PD20 FEV1 histamine, mg,
mean7 SD
0:2470:70n 0:1170:39w 0:2270:56z
Smoker/nonsmoker (%) 25/276 (9/91) 17/144 (12/88) 42/420 (10/90)
nn ¼ 152:
wn ¼ 118:
zn ¼ 270:
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As a general recommendation patients should
rinse their mouth after inhalation with a gulp of
water.
Efficacy assessments and use of asthma
medication
Lung function. Spirometry (FEV1, FVC, and FEV1 %
predicted normal) was performed on a routine basis
at the outpatient department during the 5 years of
the follow-up using a Vitalograph compact spirom-
eter (Vitalograph Ltd., Buckingham, UK).
Asthma symptoms. Asthma symptoms were re-
gistered during 2-week periods prior to clinic visits
and by asking the patients for cough, shortness of
breath at rest and during/after exercise, chest
tightness, and night-time awakenings due to
asthma.
Exercise tolerance. Exercise tolerance was esti-
mated by asking the patient and classified as
normal, acceptable or poor.
Exacerbations. The definition of an exacerbation
was hospitalization or emergency room visit be-
cause of asthma, use of a course of oral corticos-
teroids or doubling or more of the dose of the
inhaled corticosteroid.
Drug usage. Patients were asked about their use
of budesonide during the last month and whether it
was in accordance with the actual prescription. The
use of any additional asthma medication was
recorded. At the follow-up examination some
patients were not treated with budesonide Turbu-
haler but were using another inhaled corticosteroid
(beclomethasone dipropionate, BDP, or fluticasone
propionate, FP). The doses were then calculated as
follows: 200 mg budesonide Turbuhaler ¼ 200 mg FP
Diskhaler/Diskus ¼ 400 mg BDP pressurised me-
tered-dose inhaler (pMDI)/Diskhaler/Easyhaler.10–13
Treatment goals. The goals for asthma manage-
ment and treatment are given in international1 and
national guidelines.2 Treatment should aim at a
normal lung function (or best possible), normal
exercise tolerance, normal night-time sleep, no or
minimal use of reliever medication, no exacerba-
tions, and no side effects of drugs.
Safety assessments
Patients were asked about adverse experiences
including local side effects at regular clinic visits.
Routine laboratory tests such as erythrocyte sedi-
mentation rate, peripheral blood counts, blood
glucose, serum creatinine, natrium and potassium,
liver enzyme tests and urinalysis were performed at
regular intervals at least once a year. Tests of the
hypothalamic-pituitary-adrenal axis (serum and 24-
h urinary cortisol, ACTH tests) were performed only
in specific cases on high-dose treatment or in cases
of electrolyte disturbances.
At clinic visits inspection of throat was routinely
done for detection of clinically important orophar-
yngeal candidiasis.
Statistical analysis
Group mean values of budesonide doses, baseline
lung function and PC20 values and percentages of
achieved treatment goals were compared with t-
tests. Differences in changes in lung function values
were analysed using an analysis of variance
(ANOVA) with baseline FEV1 as a covariate. P values
o0.05 were considered statistically significant.
Calculations on changes in FEV1 over time included
all patients with data at each time point. Separate
calculations were performed from time 0 to 1 year,
and from time 0 to the 5-year endpoint. The slopes
were estimated with a mixed effect model: SAS
Proc Mixed procedureFSAS Institute.14 Regression
estimates were adjusted for patient differences in
number of observations contributing to the model
and for within-patient variations. Fixed effects
were time, with baseline FEV1, age and sex as
covariates.
Results
The results are presented in Tables 2 and 3 and in
Figs. 1 and 2.
Patients withdrawn from the study
There were 58 patients that we could not follow for
5 years (group A 48, group B 10 patients). As a
group the withdrawn patients were young (mean
age 27 years), had a mild disease with 37 of them
having a baseline FEV1480% predicted normal.
The patients had been withdrawn for various
reasons; considered themselves healthy without
need for medication (n ¼ 16), did not accept an
inhaled corticosteroid as further treatment (n ¼ 5),
did not return to scheduled visit (n ¼ 22), and
moved to other cities (n ¼ 15). Nobody was with-
drawn because of adverse events.
Doses of budesonide
The initial doses of budesonide were 7857133 mg
(mean7SD) in group A and 10627287 mg in the B
group. Based on clinical judgements (symptoms,
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use of reliever medication, PEF, sleep, exercise
tolerance) the dose of budesonide was then
adjusted up or down. The mean doses and dose
ranges after treatment for 5 years are shown in
Table 2. After 5 years 43 patients (17%) in the early
treatment group had been advised to stop treat-
ment with the inhaled corticosteroid. Twenty-two
of these patients reported taking an inhaled
corticosteroid intermittently during a pollen sea-
son, when otherwise exposed to allergens, or in
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Table 2 Five-year follow-up data.
Early treatment (Group A) Delayed treatment (Group B)
Number of patients (%) 253 (84%) 151 (94%)
Female/male 156/97 72/79
At start After 5 years At start After 5 years
Budesonide, mean dose7 SD 7857133 mg 412776 mg 10627287 mg 8257165 mg
(dose range) (400–1600 mg) (0–1600 mg) (400–1600 mg) (0–2400 mg)
No of patients (%) not using 100 43 (17%) 100 5 (3%)
an inhaled corticosteroid
Mean FEV1 % predicted 80.3% 93.9% 75.6% 84.5%
normal (range) (52–97%) (73–132%) (36–102%) (54–115%)
Mean PEF % predicted 83.1% 95.0% 74.0% 87.2%
normal (range) (48–114%) (78–136%) (38–117%) (51–109%)
Use of asthma maintenance
medications (% of patients):
LABAn 0% 6% 0% 64%
Theophylline 13% 0% 62% 25%
LRAw 0% 4% 0% 21%
Otherz 7% 0% 36% 8%
Local side effects, no of patients (%) 0 (0%) 4 (1.6%) 1 (0.7%) 6 (4.2%)
nLABA ¼ long-acting inhaled b2-agonists.
wLRA ¼ leukotriene receptor antagonist.
zOther ¼ disodium cromoglycate, nedocromil sodium, oral b2-agonists, antihistamine.
Table 3 Per cent patients achieving treatment goals.
Treatment goals Early treatment
(Group A)
Delayed treatment
(Group B)
Difference
Lung functionX 90% 77% 41% Po0:001
predicted normaln
Normal exercise 72% 20% Po0:001
Tolerancew
Normal sleepw 92% 75% NS
Use of reliever medication p3 doses per
week
68% 29% Po0:001
Exacerbationsz per patient per year 0.07 0.34 Po0:001
NS ¼ not statistically significant.
nFEV1 or PEF.
wSelf-reported.
zHospitalization, emergency room treatment, course of oral corticosteroids (group A 84 exacerbations, group B 243).
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association with an upper respiratory tract infec-
tion. In the delayed treatment group five patients
(3%) were treated without inhaled corticosteroids
at the 5-year follow-up. Seventeen patients were
using another inhaled corticosteroid. The mean
doses at the 5-year follow-up between the early
and delayed treatment groups are shown in Fig. 1.
The difference in mean doses between the groups
was statistically significant (Po0:001).
Self-reported compliance, checked at clinic
visits, was 92%.
Lung function
Lung function, measured both as FEV1 and PEF,
improved in both early and delayed treatment
groups 5 years after starting treatment (Po0:001
for early and Po0:01 for delayed treatment). The
difference between the groups in achieved lung
function values was statistically significant
(Po0:001). As the difference in baseline FEV1 and
PEF between the early and delayed treatment
groups was taken into account in the analysis the
results reflect the difference in disease duration
and not in disease severity. The mean values of
FEV1 and PEF after 5-year treatment are shown in
Fig. 1. It can also be noted that the improvement in
FEV1, measured as per cent predicted normal
values, improved much more rapidly in the early
treatment group compared with the delayed treat-
ment group (Fig. 2). The difference in change in
FEV1 between groups A and B from start and to 1
year was statistically highly significant (P ¼ 0:0002)
and also from start to the 5-year endpoint
(Po0:001).
Subgroup analysis. The development of lung
function in the subgroup of patients in the delayed
treatment group with baseline FEV1 values above
80% predicted normal is also illustrated in Fig. 2.
These subgroup patients had an initial mean FEV1 of
83.1% predicted normal. These mean FEV1 pre-
dicted normal values after treatment for 0.5, 1, 3
and 5 years were 86.1%, 86.0%, 87.1% and 87.6%
predicted normal, respectively. The change in FEV1
between this subgroup of group B and group A was
very different with group A patients improving
much more rapidly during the first treatment year
(Fig. 2). The difference in change was statistically
significant (P ¼ 0:0001). The FEV1 slopes over 5
years were not, however, statistically significantly
different between the subgroup of group B patients
and the rest of the group B population (P ¼ 0:39).
Achievement of treatment goals
Achievements of asthma treatment goals are given
in Table 3. Early treatment resulted in statistically
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Figure 1 Mean inhaled corticosteroid dose and mean per cent predicted normal of FEV1 and PEF after 5 years
treatment in asthma patients with early or delayed introduction of treatment with budesonide Turbuhaler.
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Figure 2 Mean FEV1 values (% predicted normal) in
patients with early (A) or delayed (B) intervention with
budesonide. Bsubgroup denotes the group B patients with
individual baseline FEV1 values 480% predicted normal.
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significantly higher percentages of achieved goals
for lung function, exercise tolerance, exacerba-
tions and use of as-needed reliever medication.
Adverse events
Three serious adverse events were recorded; one
patient was hospitalized for pneumonia, one
because of a renal stone, and one as a consequence
of a traffic accident. None of them was considered
related to the treatment with budesonide. No bone
fractures or cataracts were reported.
A total of 14 ACTH tests had been performed in
patients on higher doses of budesonide (41200 mg
per day) and all showed a normal response.
Excretion of urinary cortisol during 24 h was
analysed in 36 patients with normal result in all
but one. This 57-year-old woman had a borderline
value which was normal on the same dose (800 mg
per day) 3 month later.
Discussion
Inhaled corticosteroids reduce mortality, hospitali-
zations, emergency room visits, days missed from
work or school, use of reliever medication, and
overall costs for medication.15,16 Regular use of
inhaled corticosteroids, even taken once daily,17
prevent asthma exacerbations and higher daily
doses appear more effective than lower doses in
patients with persistent asthma.9,18
Clinical studies in Finland in the early 1990s
showed that in patients with early mild-to-moder-
ate asthma treatment with budesonide was more
effective than regular treatment with the inhaled
bronchodilator, terbutaline.3 A recent study in
Finnish children showed an advantage of budeso-
nide in comparison with disodium cromoglycate
(DSCG). Also intermittent budesonide treatment,
after initial treatment with a higher regular dose,
was more effective in preventing asthma exacer-
bations than DSCG.19 A retrospective cohort study
demonstrated a statistically significant negative
correlation between duration of asthma symptoms
when starting treatment with an inhaled corticos-
teroid and the response to treatment in terms of
improved lung function.5 Similar results have been
reported in studies from other countries, in
children6 as well as in adults with asthma.20
The results of the Finnish studies together with
the gained clinical experience were utilized in the
Finnish national asthma programme 1994–2004
issued by the Ministry of Social Affairs and Health.2
Half-way through (1999) the results of this pro-
gramme indicated that the expected results in
terms of reduced morbidity, mortality and cost-
effectiveness could be fulfilled.21
At our hospital the strategy of early use of
inhaled corticosteroids in patients with persistent
asthma was early adopted. In the late 1980s one
reason why patients refused to take inhaled
corticosteroids was the high frequency of local side
effects: approximately 25% of the patients using a
pressurized metered dose inhalers (pMDIs) contain-
ing corticosteroids developed sore throat, voice
problems or oropharyngeal candidiasis.22 We rea-
lized, however, that changing inhalation device
from a pMDI to an inspiratory flow driven dry
powder inhaler with an appropriate inbuilt resis-
tance (Turbuhalers) and containing pure drug
substance (budesonide) without carrier powder
(lactose) almost completely abolished the local
side effects.22 We therefore decided to use
budesonide Turbuhaler as our first-line inhaled
corticosteroid, which in addition, was reported to
have an improved systemic safety profile compared
with the previously used inhaled corticosteroid,
BDP.23 We were also able to demonstrate that half
the dose of budesonide Turbuhaler resulted in the
same degree of clinical efficacy as twice as
much BDP administered via pMDI.10 This finding
has been confirmed in studies using a dose-
reduction study design or a dose–response design
with at least two doses of one of the inhaled
corticosteroids.11,24
We mostly used a starting dose of 400 mg twice
daily and then applied a step down and step up
strategy depending on necessity. A high or low
starting dose has been widely discussed,25 espe-
cially as the dose response curve for inhaled
corticosteroids is fairly flat.26 A Dutch study showed
no difference in efficacy between a 200 and 800 mg
per day of budesonide.27 These patients, however,
had a normal airway function at entry into the
study. Similarly, a Finnish study showed no statis-
tically significant difference in airway function
(FEV1, PEF) between 800 mg/day budesonide com-
pared to 200 mg/day as an initial treatment dose.28
The higher dose, however, gave a more marked
decrease in BHR and reduction in serum markers of
asthmatic inflammation; serum ECP P ¼ 0:008 and
serum EPX P ¼ 0:005 for high vs. low dose budeso-
nide.28 We also reported the results of a double-
blind, placebo-controlled study in patients with a
duration of asthma symptoms o1 years compared
with a group with symptom duration42 years.29 In
patients with early asthma no difference in efficacy
was seen between 100 mg twice daily and 400 mg
twice daily, but in the patients with a longer
duration of asthma symptoms (median 5 years) the
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higher dose resulted in statistically significantly
better airway function and asthma control.
It is obvious that asthma severity differs among
individuals whatever group of patients is included
in clinical studies. Disease severity may also easily
be underestimated. We therefore consider the best
strategy to be to initiate treatment on a reasonably
high dose level but thereafter adjust the dose to
the lowest possible maintenance dose, which
usually, when budesonide is used, can be given
once daily. It should be remembered, however, that
patients with mild early asthma respond equally
well to low doses. This was clearly seen in one part
of the OPTIMA study in patients with mild persistent
asthma not previously treated with inhaled corti-
costeroids and now receiving budesonide Turbuha-
ler 100 or 200 mg twice daily18 and in the START
study with budesonide Turbuhaler 200 or 400 mg
once daily.17
The results of this follow-up study show the
advantages of early treatment. This was true not
only of airway function and asthma symptoms but
also of doses of budesonide used and requirement
of additional asthma medications. In fact, for all
studied variables early treatment resulted in
significantly higher degree of achieved treatment
goals except for night-time awakenings. This
exception could be due to the large use of inhaled
long acting b2-agonists in the delayed treatment
group. It should be noted that inhaled long-acting
b2-agonists had been considered necessary in 62%
of the patients in group B (vs. only 6% in group A)
and this had probably influenced the night-time
sleep in a positive way in this group of patients. It is
therefore obvious that early treatment is not only
more effective resulting in better airway function
and asthma control but also associated with lower
treatment costs because of less maintenance
medication and fewer exacerbations.
In the present study patients with early asthma
(group A) had higher FEV1 and PEF values when
starting treatment with budesonide than patients
in group B. However, the proportion of patients in
each group having mild or moderate asthma,
respectively, did not differ between the groups.
The difference in baseline airway function was
included as a covariate in the statistical analyses.
We therefore conclude that the difference in
treatment response between the early and delayed
treatment groups was due to a difference in
duration of asthma and not in disease severity. In
addition, we did a subgroup analysis on group B
patients with an FEV1 valueX80% predicted normal
at baseline, i.e. a subgroup having a mean FEV1
above that of group A patients. Nevertheless, group
A patients with a shorter duration of asthma
symptoms responded significantly better to treat-
ment, indicating that the duration of asthma
symptoms when starting treatment was a more
important factor for the response than the baseline
airway function. It can also be added that the
proportion of smokers did not differ between
groups A and B and smoking habits can therefore
not explain the difference in response between the
groups. The majority of patients withdrawn from
the study belonged to group A and represented the
short-duration type of asthma patients included in
the study. We have consequently excluded the
possibility that the results would have been
influenced by more severe patients leaving the
study.
The tolerability of budesonide was good in both
treatment groups but obviously any risk of adverse
events should be lowest in a group of patients with
the lowest maintenance doses of the drug. In this
study a 50% lower maintenance dose could be
achieved with early introduction of budesonide,
which also resulted in almost one-fifth of the
patients (17%) being able to discontinue their
budesonide treatment. Early introduction of in-
haled corticosteroids is therefore the safest way of
using these drugs for treatment of asthma.
This study shows the importance of early
introduction of inhaled corticosteroids in patients
with persistent asthma. Early treatment results in
significantly better improvements in airway func-
tion, exercise tolerance, lower risk of exacerba-
tions and less use of additional asthma medications
as well as of as needed reliever medication. These
obvious benefits can be achieved with significantly
lower maintenance doses of budesonide thereby
further reducing the risks of long-term side effects.
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